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The beautiful Thorskog Castle just north of Go¨teborg on the Swedish west coast was the venue for the 134th Nobel
Symposium, entitled ‘‘The Adipocyte: A Multifunctional Cell.’’ For three splendid summer days, some 50 scientists working
on various aspects of adipocyte biology convened under the auspices of the Nobel Foundation.Advances over the last two decades in our understanding of the
adipocyte have clarified its role as a key regulator of both energy
balance and intermediary metabolism. It is now known that, in
addition to being an insulator and energy depot, the adipocyte
is a highly active cell, secreting a wealth of factors, including
leptin, that play a part in CNS and appetite regulation. There is
also a much greater understanding of how fat cells develop
from precursor cells through upregulation of the nuclear recep-
tor PPARg, which is also the receptor for the antidiabetic thiazo-
lidinedione drugs.
Despite this new information, effective treatments for obesity
and its related diseases have not been developed as quickly as
hoped. One of the goals of this meeting was to highlight new
potential targets in adipocyte biology for therapeutic inter-
vention for the treatment of obesity and related disorders. The
focus of the meeting was therefore on projects with the potential
to deliver new drug targets such as white versus brown adipo-
cyte differentiation, adipocyte metabolism, and inflammation.
The adipocyte and human health
Obesity has escalated in many regions of the world to epidemic
proportions: more than 1.1 billion people are estimated to be
overweight, of which 320 million are now considered obese.
Findings related to obesity from the WHO, cited by Paul Zimmet
(International Diabetes Institute, Australia), indicate that type 2
diabetes and cardiovascular disease cause twice as many
deaths as infectious disease, maternal/perinatal conditions,
and malnutrition combined. If no action is taken, obesity will
lead to the death of 338 million worldwide, mainly from chronic
diseases like diabetes and cardiovascular disorders.
Obesity is very strongly linked to type 2 diabetes. This has led
to the term ‘‘diabesity’’ to best describe the epidemic. The
number of people with diabetes will almost double over one
generation from the present 190 million to 335 million in 2025.
Another alarming fact is that 10%–15% of children in developed
nations are now overweight or obese. Thus, a new generation will
enter adulthood with an unprecedented level of obesity.
Allelic variations and mutations are important in how we
respond to a hypercaloric environment. In his keynote address
in memory of the late Per Bjo¨rntorp, Steve O’Rahilly (University
of Cambridge, UK) discussed disease-linked mutations and
their pathogenic relevance. Most monogenic forms of obesity
are rare; for instance, only eight families with congenital leptinCELL METABOLISM 4, 425–427, DECEMBER 2006 ª2006 ELSEVIER INdeficiency have been identified so far, as well as a limited
number of disease-causing mutations in the leptin receptor.
However, in a select population with childhood-onset massive
obesity, mutations in the melanocortin-4 receptor (MC4R) are
found at a frequency of approximately 5.5%. In the general UK
population, the number is 1 in 1000; this frequency is far greater
than that of cystic fibrosis.
Adipocyte differentiation
Even though we have learned much during the past decades re-
garding adipogenesis, most of this new information has dealt
with rather late steps of adipogenesis (e.g., factors important
for lipid accumulation like C/EBPs and PPARg); very little is
known about the earliest commitment to the adipose lineage.
Undifferentiated mesenchyme has the capacity to mature into
brown and white adipocytes. While the exact nature of this pro-
cess remains obscure, increasing data suggest that Wnt signal-
ing is involved. Experiments in cultured cells show that some
Wnts stimulate adipogenesis while others, such as Wnt10b,
block preadipocyte formation and shift cell fate toward the oste-
oblast lineage (Ormond MacDougald, University of Michigan). In
this process, SFRP5 signals from mature adipocytes to stimu-
late recruitment of more adipocytes. BMP4 also can act in a
stimulatory molecule on recruitment of preadipocytes, as well
as in general PKA signaling (Daniel Lane, Johns Hopkins Univer-
sity; Karsten Kristiansen, University of Southern Denmark). Dur-
ing the later phase of differentiation, a new subdomain of the
PPARg molecule, located within helices 7 and 8 of the ligand-
binding domain, might contribute to fine tuning of lipid synthesis
within the adipocyte. Mutations in this region, K365R and
F372A, attenuate lipid accumulation in Swiss fibroblasts, while
the response to TZD remains unaltered (Steve Farmer, Boston
University).
Brown adipocytes are present in human adipose tissue under
normal conditions and are known to expand in response to
adrenergic stimuli, such as in patients with pheochromocytoma.
These patients display an expansion of ucp-1-positive brown
adipose tissue (BAT) cells; mitochondrial uncoupling via UCP-1
likely contributes to the lean phenotype typically observed.
Thus, BAT is normally present and can most likely be induced
and function in the context of human adaptive thermogenesis.
Promoting brown fat differentiation is therefore potentially a
very attractive way to counteract both diet-induced andC. DOI 10.1016/j.cmet.2006.11.009 425
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differentiation is regulated is thus probably the most important
feature of early adipocyte commitment. Harnessing the pro-
cesses that enhance brown fat differentiation and increase en-
ergy expenditure could lead to effective therapies. In mature
human adipocytes, forced expression of PGC-1a induces a
brown-fat-like phenotype including induction of ucp-1 and other
mitochondrial genes (Dominique Langin, INSERM, France).
However, the response of typical white adipocyte PPARg
targets to PPARg agonists is not altered by PGC-1a. While this
reveals a high degree of plasticity in the mature white fat-cell
phenotype, it also argues in favor of differences in early lineage
specificity being the underlying mechanism in differentiation of
bona fide brown adipocytes. Thus, white adipocytes can attain
many typical BAT features but still maintain a white adipocyte
phenotype. Induction of PGC-1a in white adipocytes could be
a way to induce mitochondrogenesis and a capacity to convert
excess energy depots to heat. Bruce Spiegelman (Harvard Uni-
versity) reviewed the evidence that PPARg, supported by the
C/EBP proteins, is the fundamental pathway driving fat-cell
differentiation. Spiegelman also introduced an interesting new
regulator of lineage selection. When expressed together with
PPARg in fibroblastic cells, prdm16 is capable of inducing
most, if not all, aspects of brown fat-cell differentiation, including
induction of ucp-1. Activation of this factor could prove to be the
branching point in early cell-fate determination between white
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head transcription factor FOXC2 was discussed as a possible
downstream target of prdm16 and as an upstream regulator of
PGC-1a. Thus, activation of prdm16 could prove to favor expan-
sion of the BAT compartment. C. Ronald Kahn (Joslin Diabetes
Center) proposed that early cell-fate decisions regarding brown
versus white fat-cell precursor lineage selection might involve
expression of necdin, RIP140, and Prdm16. Kahn suggested
that, based on differences in expression profiles of certain
developmental genes—e.g., Hoxa5, Tbx15, and glypican—
distinct classes of white adipocytes might, in a selective
manner, populate the different adipose tissue depots. It is well
known that the interscapular brown fat depot in rodents is highly
innervated by the sympathetic nervous system. With this in mind,
it is very likely that depot-specific sympathetic innervation in hu-
mans could be of therapeutic interest in terms of induction of
brown fat adipogenesis and early cell-fate decisions. This is sup-
ported by the findings of Tim Bartness (Georgia State University),
who has used pseudorabies virus (PRV) tracings to show that ad-
ipose tissue receives depot-specific innervation; this could also
play a role in adipocyte metabolism (see below).
Adipocyte metabolism
Although control of food intake would seem to be poorly regu-
lated on a day-to-day basis, weight regulation operates with
more than 99% precision over the lifetime of most individuals,
strongly suggesting a mechanism of fine regulation. One of the
most important factors in this mechanism is the adipocyte-
secreted hormone leptin. As a general regulator of many physio-
logical systems, leptin plays a part in the treatment of conditions
like lipodystrophy and amenorrhea (Jeff Friedman, Rockefeller
University).
Depot-specific regulation of metabolic activity such as lipo-
lysis results from differences in gene expression. It has been
suggested that it could also be maintained by differences in
innervation. Using PRV tracings, Tim Bartness demonstrated a
direct CNS-mediated sympathetic innervation of adipose tissue
depots. PRV-labeled sympathetic outflow neurons colocalize
extensively with MC4R mRNA. These findings open up the dis-
tinct possibility that depot-specific sympathetic innervation
could be an important regulator of adipocyte metabolism and
could, to some extent, explain previous findings regarding depot
differences in lipolysis. Thus, hypothalamic leptin-dependent
sympathetic efference could, in a depot-specific manner, affect
metabolism.
Members of the FOXO family of transcription factors are im-
portant regulators of insulin-dependent adipose differentiation.
This mechanism contributes to recruitment of new adipocytes
in times of plenty (Domenico Accili, Columbia University). In an
RNAi-based approach, Michael Czech (University of Massachu-
setts) showed that depletion of the transcriptional corepressor
RIP140 and the protein kinase MAP4K4 upregulates a cluster
of genes in the pathway of glucose uptake, including GLUT4.
Mechanistically, GLUT4 associates with the Akt substrate
AS160, a Rab GAP domain-containing protein. A crucial step
in insulin-dependent regulation of GLUT4 docking to the plasma
membrane is binding of 14-3-3 proteins to GLUT4-associated
AS160 (David James, Garvan Institute, Australia).
Another interesting target for intervention is the retinol-bind-
ing protein 4 (RBP4), which is secreted from adipocytes and is
elevated in insulin-resistant subjects. Circulating RBP4 is boundCELL METABOLISM : DECEMBER 2006
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synthetic retinoid fenretinide, which leads to the elimination of
RBP4 via the kidney. While the exact mechanism of action is
under investigation, this treatment nevertheless improves insulin
and glucose tolerance (Barbara Kahn, Harvard University).
Leslie Kozak (Pennington Biomedical Research Center)
discussed the possibility that epigenetic mechanisms acting
on adipocyte differentiation could predispose an individual to
diet-induced obesity.
Inflammation and adipocyte function
Obesity is associated with chronic low-grade inflammation in
adipose tissue. This was first suggested by the work of Go¨khan
Hotamisligil and Spiegelman, demonstrating that fat cells
secrete TNF-a in the context of obesity. In fact, it now appears
that obesity generates conditions that increase the demand on
the endoplasmic reticulum (ER) and trigger the activity of stress
and inflammatory signaling pathways including c-Jun N-ter-
minal kinase (JNK). Based on experiments in which JNK-1
deficiency was shown to reverse ER-stress-induced insulin
resistance, Hotamisligil (Harvard University) discussed the inter-
esting possibility of using ER/JNK-1 as a target for treatment of
insulin resistance and type 2 diabetes.
Similarly, leptin, apart from regulating body weight and repro-
duction, can also be regarded as a proinflammatory cytokine.
Leptin stimulates CD4+ Th1 cells that produce interferong, whichCELL METABOLISM : DECEMBER 2006might play a role in development of insulin resistance (Graham
Lord, Harvard University). Bente Klarlund Pedersen (University
of Copenhagen, Denmark) showed in a series of human in vivo
studies that IL-6 is produced by the contracting muscle and is
subsequently released into circulation, where it activates lipoly-
sis and fat oxidation. This demonstrates that, in addition to being
associated with insulin resistance, IL-6 can have beneficial
in vivo effects. This suggests that ligands to the IL-6R/gp130b
receptor complex could be interesting as new drug targets.
Despite immense efforts so far, no effective treatment has
been made available to help individuals coping with the conse-
quences of living in a ‘‘hypercaloric society’’ in which calories
are cheap, accessible, and sometimes also palatable. Much
attention has been on central mechanisms that regulate behav-
ior, food intake, etc., and the purpose of this meeting was to
highlight the role of peripheral tissue, with a clear focus on the
adipose. The interface between central regulation and peripheral
response might constitute an accessible route to new drug tar-
gets that might, for example, regulate adipocyte differentiation.
This could provide a mechanism to dissipate excess calories.
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